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Abstract
Cytomegalovirus is highly prevalent worldwide and an important opportunistic pathogen in human 
immunodeficiency virus (HIV)–infected individuals. The effects of cytomegalovirus infection on 
HIV-exposed infants are poorly understood. We conducted a systematic review to assess the 
relationship between cytomegalovirus and HIV infections among HIV-exposed infants. Limited 
evidence suggests that HIV-induced immunosuppression in the mother increases the rate of 
congenital cytomegalovirus infection, while maternal antiretroviral therapy may reduce it. Limited 
information exists on the direction of the relationship between cytomegalovirus and HIV 
transmission among HIV-exposed infants. Only 2 studies have addressed this temporal sequence of 
events, and they suggest that cytomegalovirus can lead to subsequent HIV infection in HIV-
exposed infants. Most evidence suggests that early cytomegalo-virus infection accelerates HIV 
disease progression in infants. Gaps remain in understanding the role that cytomegalovirus 
infection plays in HIV-exposed infants. Decreasing cytomegalovirus transmission prenatally and in 
infancy might further decrease HIV transmission and lead to better health among HIV-exposed 
infants.
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Cytomegalovirus (CMV) infection is highly prevalent worldwide. In human 
immunodeficiency virus (HIV)–infected individuals, CMV is an important pathogen, even 
though the advent of effective antiretroviral therapy (ART) has made opportunistic infections 
with CMV less common. CMV seropositivity is still associated with increases in non–AIDS-
related events and non–AIDS-related death among HIV-infected individuals [1]. CMV may 
also play a role in HIV disease progression [2–8].
CMV can be transmitted in utero, during the intrapartum period, and postnatally via 
breastfeeding, and horizontally, through contaminated secretions such as saliva or urine. 
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Congenital disease can be a source of considerable morbidity, whereas postpartum infection 
is typically asymptomatic in healthy, full-term infants [9]. However, in resource-limited 
settings, CMV has been suggested as a cause for morbidity and decreased growth in infants 
of HIV-infected mothers, even in HIV-uninfected infants [10, 11]. Additionally, symptomatic 
perinatal CMV infections have been described in infants exposed to but uninfected with HIV 
(hereafter, “HIV-exposed-uninfected infants”) [12]. This population of infants is increasing 
in magnitude worldwide because of the successes in decreasing mother-to-child transmission 
(MTCT) of HIV [13].
CMV has also been hypothesized as a cofactor in the transmission of HIV from mother to 
child. There are several potential pathways that could mediate such an effect. CMV and HIV 
can infect the same cell types, with direct coinfection leading to enhanced HIV replication. 
CMV can also enhance other coreceptor pathways for HIV entry, transactivate viral long 
terminal repeats, and cause inflammation and immune activation, all of which can enhance 
HIV replication in vitro [2–8, 14, 15].
While there is evidence of an association of in utero CMV and HIV infections in infants, the 
temporal sequence of transmission events is not well understood. Whether the burden of 
infant CMV infection is higher among infants of HIV-infected mothers, particularly in the 
era of effective ART, is also unclear. In addition, the role of CMV as a cofactor in HIV 
disease progression during infancy is not well characterized. We conducted a systematic 
review of the published scientific literature to assess the relationship between CMV and HIV 
infection in infants.
METHODS
Study Questions
We investigated 5 questions in this systematic review. For each question, the study inclusion 
criteria are shown.
First, we sought studies that investigated whether HIV-exposed infants are more likely to 
acquire CMV infection, compared with HIV-unexposed infants. Studies were included if 
they determined infant CMV infection by 6 months of age and compared CMV infection 
rates by infant HIV-exposure status.
Second, we searched for studies that considered the effect of prenatal/postnatal antiretroviral 
exposure on transmission of CMV infection to the HIV-exposed infants. Studies were 
included if they reported information on maternal ART during pregnancy and/or 
breastfeeding, determined infant CMV infection status and the timing of infection, and 
compared infant CMV infection rates by maternal antiretroviral status.
Third, we looked for research that evaluated whether HIV-infected infants are more likely to 
acquire CMV infection, compared with HIV-exposed-uninfected infants. Studies were 
included if they determined infant HIV infection status in the first 6 weeks of life, 
determined infant CMV infection, and compared CMV infection rates by HIV status.
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Fourth, we sought studies that addressed whether early CMV infection increases the risk of 
subsequent MTCT of HIV. Studies were included if they determined infant CMV infection 
in the first 6 months of life and determined infant HIV infection status and the timing of 
infection.
Fifth, we looked for investigations that considered whether infants coinfected with HIV and 
CMV have faster HIV disease progression during infancy. Studies were included if they 
included children perinatally infected with HIV who were <1 year old, tested for CMV 
infection in the first year of life, included at least 1 measure of HIV disease progression as 
an outcome (including death), and made comparisons by CMV status.
Literature Search
Medline, Embase, CINHAL, CAB Abstracts, Global Health, Web of Science, FedRIP, 
LILAC (PAHO/WHO), WHOLIS, and the Cochrane Library databases were searched for the 
following terms: (prenatal OR postnatal OR perinatal OR congenital OR Infant OR fetus OR 
newborn OR fetal OR baby OR babies) AND (cytomegalovirus OR CMV OR HCMV) AND 
(HIV OR “human immunodeficiency virus”). Results were limited to studies published in 
English. No restrictions on publication year were used; the search was last conducted on 30 
March 2015.
All abstracts and titles were screened for relevance to each of the 5 review questions. Only 
publications reporting results from original studies were included. The full text of all 
relevant articles was reviewed by 2 authors (K. E. A. and A. P. K.) independently, to 
determine whether they met eligibility criteria for any questions assessed in this systematic 
review. The third author (S. R. E.) resolved discrepancies. For each included study, the 
following data were abstracted: (1) objective, (2) study design, (3) population, (4) results, (5) 
methodologic strengths, and (6) methodologic weaknesses. Fisher exact P values were used 
to compare proportions for studies that did not provide a statistical test or did not specify the 
statistical test.
RESULTS
The search results yielded 1186 articles. After removing duplicate references and screening 
titles and abstracts, we reviewed the full text of 102 articles. There were 6 discrepancies 
resolved by the third reviewer. In total, 19 studies met the eligibility criteria for at least 1 
question of the systematic review.
Are HIV-Exposed Infants More Likely to Acquire CMV Infection, Compared With HIV-
Unexposed Infants?
Five studies met the eligibility criteria to be included in this assessment [10, 16–19]. A 
cross-sectional study of neonatal admissions in Zambia examined the prevalence of 
congenital CMV infection, determined by detection of CMV DNA in saliva, urine, or serum 
or detection of immunoglobulin M (IgM) antibody in serum in the first 3 weeks of life [17]. 
Congenital CMV infection was detected in 11.4% (9 of 79; 95% confidence interval [CI], 
6.1%–20.3%) of HIV-exposed neonates, compared with 2.1% (6 of 293; 95% CI, .8%–4.6%) 
of unexposed neonates. Maternal HIV infection was independently associated with an 
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increased odds of congenital CMV infection, compared with no maternal infection (odds 
ratio [OR], 6.66; 95% CI, 2.13–20.88; P = .001). As this study was not population-based—
the point of entry was hospital admission of a sick neonate—results may not be 
generalizable. An Italian study used CMV-specific polymerase chain reaction (PCR) 
analysis to examine cord blood obtained using the dried blood spot technique from 
newborns of women with and those without HIV infection. The study found that 3 of 187 
HIV-exposed infants (1.6%) had congenital CMV infection, compared with 0 of 372 infants 
born to HIV-uninfected women (P = .04) [19]. A limitation of this study was that it only 
tested cord blood samples, which could underestimate CMV prevalence. A study in Zambia 
found a significant difference in the proportion of infants with high serum CMV DNA loads 
at 6 months: 6 of 67 HIV-exposed infants (9%), compared with 7 of 235 HIV-unexposed 
infants (3%), had a CMV DNA load of >50 copies/mL (P = .044) [16].
Two other studies yielded different results. A cohort of infants (with or without HIV 
exposure) recruited into a trial of micro-nutrient-fortified complementary foods in Zambia 
provided information on rates of CMV infection, as screened by serum CMV DNA at age 6 
months [10]. The infants were representative of the region. CMV DNA was detected in the 
serum of 55 of 120 HIV-exposed infants (45.8%) and 152 of 393 HIV-unexposed infants 
(38.7%); the difference was not statistically significant. A study from Brazil examined rates 
of congenital CMV infection among HIV-exposed infants, compared with unexposed 
infants, from a CMV-immune, low-income population; only 8.7% of HIV-infected mothers 
had an AIDS-defining condition, and none had late-stage HIV infection [18]. No difference 
was observed in rates of congenital CMV infection, defined as CMV detection in the urine 
by PCR or culture by age 15 days, by HIV-exposure status (2.7% vs 2.9% in infant with and 
those without HIV exposure, respectively). Of interest, perinatal CMV infection (defined as 
detection of viruria during age 1–3 months) was detected in fewer HIV-exposed infants than 
HIV-unexposed infants (7.9% vs 39.4%; P < .001); most infants (93.9%) in the latter group 
breastfed, whereas only 5.9% of HIV-exposed infants breastfed.
What Is the Effect of Prenatal/Postnatal Antiretroviral Exposure on Transmission of CMV 
Infection to HIV-Exposed Infants?
Most of the evidence on the frequency of congenital CMV infection among HIV-exposed 
infants accumulated prior to the combination ART (cART) era [20–22]. However, 5 recent 
studies shed some light on this question and met the criteria to be included in this review 
[12, 20, 23–25]. The large French Perinatal Cohort Study showed lower rates of congenital 
CMV infection in HIV-exposed-uninfected infants in the cART era (1.2%), compared with 
the pre-cART era (3.5%), particularly if cART began in the first trimester (P = .004); among 
HIV-infected infants, however, rates of congenital CMV infection remained high in the 
cART era [24]. A study from the United States did not show a change in congenital CMV 
rate by maternal cART use; most mothers started cART after the first trimester in this study 
[12]. Consistently, a study of 367 HIV-exposed infants in the United States [23] found that 
congenital CMV infection was associated with higher maternal HIV load at the start of 
prenatal care (P = .02) and with maternal HIV diagnosis during pregnancy/delivery (P = .
03); thus, cART would have been started later in pregnancy or not at all in these women. 
Data from sub-Saharan Africa are limited. A study of 748 newborns of HIV-infected 
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mothers from South Africa (96% received prenatal antiretrovirals) collected saliva from 
newborns at a median age of 1 day and tested specimens for CMV via PCR analysis. The 
study reported a congenital CMV infection rate of 2.9% (22 infants); no association of 
congenital CMV infection was observed with length or type of maternal antiretroviral 
prophylaxis. However, low maternal CD4+ T-cell count (<200 cells/μL) during pregnancy 
was associated with congenital CMV (adjusted OR, 2.9; 95% CI, 1.2–7.3) [25].
Rates of perinatal/early postnatal CMV infection (defined as a positive culture result in the 
first 6 months of life) were decreased in the cART era, compared with the pre-cART era 
(8.9% vs 17.9%; P < .01) in a US cohort of 414 HIV-exposed infants [12]; maternal ART 
was associated with a decreased odds of perinatal/early postnatal CMV (OR, 0.21; 95% CI, .
07–.63). Furthermore, the likelihood of symptomatic perinatal/early postnatal CMV 
infection (symptoms included splenomegaly, lymphadenopathy, and hepatomegaly) was 
increased in infants whose mothers had not received cART, compared with those whose 
mothers were receiving cART (41% vs 6% of CMV-infected infants; P < .05) [12].
The effect of cART on breast milk CMV load was examined among 69 HIV-infected, 
lactating Malawian women [20]. There was an association between milk HIV-1 RNA and 
CMV DNA load. However, milk CMV load was similar in women who did and those who 
did not receive ART in this small sample, leading the authors to postulate that the impact of 
maternal ART on the magnitude of infant CMV exposure may be limited. Of interest, there 
was an inverse relationship between milk CMV load and infant growth [20].
Are HIV-Infected Infants More Likely to Acquire CMV Infection, Compared With HIV-
Exposed-Uninfected Infants?
Eleven studies met the criteria to be included in this assessment (Table 1) [12, 18, 21–24, 
26–30]. Ten of these addressed congenital CMV infection [12, 18, 21–24, 26, 28–30]. One 
early study in the United States examined data from 154 infants born during 1988–1995 
[21]. Congenital CMV infection (defined as infants who tested positive for CMV within 3 
weeks of birth) was more common in HIV-infected infants, compared with HIV-exposed-
uninfected infants (Table 1). Additionally, the first positive HIV test result was noted to be at 
an earlier mean age in infants with congenital CMV infection, compared with those without 
congenital CMV infection (8.8 vs 30.1 days), suggesting a higher frequency of in utero HIV 
infections among infants with congenital CMV infection, but this difference was not 
statistically significant (P = .10). The large French Perinatal Cohort study tested 4797 HIV-
exposed infants for CMV by urine culture in the first 10 days of life (Table 1) [24]. There 
was a significantly higher prevalence of congenital CMV infection among HIV-infected 
neonates, compared with HIV-uninfected neonates (Table 1). Similar results were seen in a 
smaller study of 51 HIV-exposed infants in Kenya [29], as well as in a retrospective case-
control analysis of HIV-exposed infants enrolled in a clinical trial comparing long and short 
durations of maternal and infant use of zidovudine for the prevention of MTCT of HIV in 
Thailand [28]. Most recently, a subanalysis of data from a study in Malawi revealed that 
congenital CMV infection was more common among infants with in utero HIV infection, 
compared with HIV-exposed-uninfected infants (Table 1) [30].
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Other studies have not shown significant differences between congenital CMV rates of HIV-
infected and HIV-exposed-uninfected neonates, although most had small samples of HIV-
infected infants (Table 1) [12, 22, 23, 26].
Of the 6 studies assessing postnatal CMV infection, most found a significantly higher rate of 
CMV infection in HIV-infected children (Table 1) [12, 18, 22, 26–28]. The study by 
Chandwani et al was the only one that found no significant difference in postnatal CMV 
rates by HIV status; however, the P value for the comparison was marginally significant 
(Table 1), and the cumulative infection rate, including congenital CMV infection, was 
significantly higher in HIV-infected children, compared with HIV-exposed-uninfected 
children (30% vs 17%; P = .010) [26].
Does Early CMV Infection Increase the Risk of Subsequent MTCT of HIV?
While there are several articles describing rates of HIV/CMV coinfection in infants (see the 
previous subsection), little research has examined whether CMV infection is associated with 
increased susceptibility to subsequent MTCT of HIV. Two studies met the eligibility criteria 
for this question; one addressed sequence of perinatal infection events, while the other 
examined postnatal infection [28, 30].
A study from Thailand analyzed results of HIV and CMV testing performed on HIV-
exposed infants over time from birth through age 18 months. The sequence of infection with 
CMV and HIV was discernable from the longitudinal data. In utero CMV infection, defined 
as a positive CMV IgM titer in cord blood or detection of CMV DNA in an infant peripheral 
blood sample obtained within 10 days of birth. Intrapartum/neonatal CMV infection was 
defined as CMV-negative cord blood and neonatal peripheral blood samples, with a serum 
sample positive for CMV IgM or DNA at 6 weeks of age. In utero and perinatal HIV 
infection were defined as a positive HIV-specific PCR test within 7 days after birth and 
between 8 days and 1 month after birth, respectively. While congenital CMV infection was 
associated with intrapartum HIV infection (P = .03), perinatal CMV infection was not 
associated with in utero HIV infection (P = 1.00). While not conclusive, this suggests that 
the timing of CMV infection may be important in determining increased susceptibility to 
HIV MTCT [28].
A more recent study examined the risk of HIV infection through breastfeeding in Malawian 
infants with early CMV infection, defined as CMV DNA detection at age 6 months. HIV 
DNA testing was performed at birth and ages 2, 12, 28, and 48 weeks. Detection of CMV in 
plasma via PCR analysis at age 6 months was not associated with an increased risk of 
subsequent HIV acquisition through breastfeeding (hazard ratio [HR], 4.52; 95% CI, .58–
35.3), while there was a marginally significant increased risk for the combined outcome of 
HIV acquisition or infant death (HR, 4.27; 95% CI, .99–18.4) [30]. The study was 
underpowered to detect a difference in HIV transmission events.
Do HIV/CMV-Coinfected Infants Have Faster HIV Disease Progression During Infancy?
Six articles met eligibility criteria for this question (Table 2) [21, 22, 26, 27, 31, 32]. 
Although our focus was disease progression during infancy, most studies reported disease 
progression for longer periods.
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Two small, retrospective studies conducted in the United States in the early 1990s assessed 
the association of CMV coinfection with mortality in HIV-infected infants [27,31].While 
one study reported a significant association (P < .05), the Fisher exact test we conducted 
yielded a P value of .095, indicating no significant difference (Table 2) [31].The second 
study also failed to find a statistically significant association (Table 2) [27].In a small 
prospective cohort study, Gabriel et al reported no difference in survival or HIV disease 
progression among perinatally HIV-infected children by CMV infection status (Table 2) 
[32].
Another study of 37 HIV-infected infants found that CMV infection in the first 6 months of 
life was associated with higher mean p24 antigen concentrations and higher mean CD8+ T-
lymphocyte proportion but not with CD4+ T-lymphocyte proportion (Table 2) [26]. A similar 
study found absolute CD4+ T-lymphocyte counts, CD4+ T-lymphocyte percentage, and 
ratios of CD4+ to CD8+ T cells were significantly lower in CMV/HIV-coinfected infants, 
compared with infants without CMV infection (Table 2). Mean survival time for CMV/HIV-
coinfected infants was 25 months, compared with 39 months for infants not infected with 
CMV; this difference was not statistically significant (Table 2) [21].
In 1999, Kovacs et al reported the results of a study that examined the association of CMV 
infection with HIV disease progression among HIV-infected infants. Infants were recruited 
from multiple high-risk obstetric clinics in the United States and followed until age 18 
months. CMV infection was assessed by urine culture at birth and every 6 months thereafter. 
Two infants had congenital CMV infection. By age 18 months, infants coinfected with CMV 
had higher rates of HIV disease progression than infants infected with HIV alone (Table 2). 
Additionally, CMV infection during the first 18 months more than doubled the risk of HIV 
disease progression (relative risk, 2.59; 95% CI, 1.13–5.95) [22].
DISCUSSION
This systematic review synthesizes the evidence on the relationship between HIV and CMV 
infections in infants but also highlights several limitations and gaps in the existing literature. 
On the question of whether HIV-exposed infants have higher rates of congenital CMV 
infection, the limited information available suggests that the main determinant may be the 
mother’s level of HIV-induced immunosuppression [10, 16–18]. Most studies in which HIV-
infected mothers were not immunosuppressed found no difference in congenital CMV 
infection rates [10, 18], whereas those with immunosuppressed women found increased 
congenital CMV infection in HIV-exposed infants. This is biologically plausible, as 
immunosuppression correlates with CMV shedding in the genital tract of HIV-infected 
women [14, 17, 29, 33]. Additionally, emerging evidence suggests that maternal ART may 
decrease the rate of congenital CMV infection [12, 20, 23–25], likely by improving maternal 
health and immunity, resulting in decreased mucosal shedding of CMV during birth and a 
reduced incidence of reinfection or disease reactivation. It is more difficult to assess any 
effects of maternal ART on postnatal CMV transmission, particularly in settings where 
breastfeeding is practiced, given generally very high rates of CMV transmission via 
breastfeeding [30, 34, 35]. As an-tiretroviral programs roll out in sub-Saharan Africa and as 
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more women initiate cART even prior to their pregnancy, studies will need to reevaluate the 
frequency of congenital, perinatal, and postnatal CMV infection in HIV-exposed infants.
The majority of studies point to an increased prevalence of congenital CMV infection among 
HIV-infected neonates, compared with HIV-exposed-uninfected neonates [21, 24, 28, 29]. 
Similarly, the available evidence indicates a higher frequency of postnatal CMV acquisition 
among HIV-infected infants, compared with HIV-exposed-uninfected infants [12, 22, 26, 
27]. This could be due to a higher degree of immunosuppression in HIV-transmitting 
mothers, with concomitant increased risk of CMV reactivation, reinfection, and shedding 
and, thus, an increased risk of CMV transmission to the infant [36]. Additionally, 
immunosuppression in HIV-infected infants may make them more vulnerable to coinfection.
Only 2 studies were found that could directly assess the question of whether early CMV 
infection increases the risk of subsequent MTCT of HIV. These 2 studies indicate that 
congenital CMV infection does increase the risk of subsequent HIV infection for infants 
during the intrapartum period [28] and postnatally [30]. Even though there is biological 
plausibility for these findings, more epidemiological evidence is needed to answer this 
question definitively.
Few studies have assessed the role of early CMV infection on HIV disease progression in 
infants, and most have small sample sizes and limited power with methodologic differences, 
making it difficult to directly compare results. Most but not all evidence suggests that early 
CMV infection accelerates HIV disease progression in infants. However, most included 
studies were conducted exclusively in the pre-cART era [21, 22, 27, 31, 32]. Of interest, 
recent, yet unpublished evidence indicates that level of CMV viremia during early life in 
HIV-infected infants is a predictor of the size of HIV reservoir after cART-induced virologic 
suppression [37], possibly through coinfection of the same long-lived memory lymphocytes.
A limitation of this review was the inconsistency in specimen type and laboratory methods 
used for detecting CMV. However, while serological analysis may detect more cases of 
infant CMV infection, several studies have demonstrated that PCR-based methods for CMV 
detection are highly correlated with serological testing [38–41]. CMV PCR testing in urine 
and saliva has very high sensitivity and specificity (>90%), compared with serological 
testing [38, 41]. Additionally, a recent study assessing the validity of PCR testing in blood 
found that PCR detected most infant CMV infections [40].
There are remaining gaps in our understanding of the role of CMV in HIV acquisition and 
health outcomes of HIV-infected infants and HIV-exposed-uninfected infants. Expanded 
access to maternal cART, starting prior to or early in pregnancy, has many benefits beyond 
directly decreasing HIV MTCT, including improvements in maternal health and immunity, 
and decreasing CMV infection risk for the infant. Decreasing CMV transmission prenatally 
and postnatally might further decrease HIV transmission risk, as well as lead to better health 
and developmental outcomes among HIV-exposed-uninfected infants. Clinical trials may 
need to assess methods to further decrease infant CMV exposure while maintaining 
breastfeeding, which has multiple proven benefits. A trial of valacyclovir starting at 34 
weeks of gestation and continuing postnatally for 12 months in mother with HIV and herpes 
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simplex virus coinfection did not affect postnatal CMV transmission via breastfeeding but 
modestly decreased cervical CMV shedding [34].Higher doses or novel anti-CMV drugs in 
the pipeline [42] may offer opportunities to further investigate the effects of inhibition of 
CMV replication in HIV-infected mothers as a way to further decrease MTCT of both 
viruses and improve infant survival and health, particularly in resource-limited countries.
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ex
po
se
d 
u
n
in
fe
ct
ed
 in
fa
n
ts
 (2
.2%
; P
 
<
 .0
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)
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e 
sa
m
pl
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o
f H
IV
-
ex
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se
d 
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fa
n
ts
 
ev
al
ua
te
d
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o 
po
stn
at
al
 C
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V
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in
g 
w
as
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n
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er
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t a
l [
29
], 
20
09
K
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, 1
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9–
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os
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V
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co
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r c
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 c
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n
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w
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t c
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ge
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ta
l C
M
V
 
in
fe
ct
io
n,
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y 
H
IV
 st
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us
Co
ng
en
ita
l C
M
V
 in
fe
ct
io
n 
w
as
 m
o
re
 c
o
m
m
o
n
 in
 H
IV
-
in
fe
ct
ed
 in
fa
n
ts
: 2
9%
 (4
 of
 
14
) o
f H
IV
-
 
in
fe
ct
ed
 
n
ew
bo
rn
s h
ad
 C
M
V
 
in
fe
ct
io
n 
co
m
pa
re
d 
to
 2
.7
%
 
(1 
of 
37
) o
f H
IV
-
ex
po
se
d 
Sm
al
l s
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pl
e 
of
 
H
IV
-
po
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iv
e 
in
fa
n
ts
 w
ith
 
co
n
ge
ni
ta
l C
M
V
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su
lts
 (n
 = 
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); 
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V
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at
us
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se
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ed
 
po
stn
at
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t 
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at
io
n 
Ye
a
r
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y 
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te
, 
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ri
od
, 
D
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ig
n
N
o.
 o
f H
IV
-
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se
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s/
C
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ld
re
n
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d
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 D
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R
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s(e
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n
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ed
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bo
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s (
P 
=
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)
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lts
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er
e 
no
t 
pr
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ed
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ra
te
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nl
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cu
m
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e 
pe
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 w
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CM
V
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io
n 
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re
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d
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ur
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et
 a
l [
23
], 
20
10
U
ni
te
d 
St
at
es
, 
19
97
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00
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re
tr
os
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ct
iv
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rt 
stu
dy
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3 
ev
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ua
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d 
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r 
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n
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l 
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V
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ct
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n
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e 
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sh
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t t
es
ta
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 c
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pa
re
 p
ro
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s o
f 
in
fa
n
ts
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ith
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nd
 th
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e 
w
ith
ou
t c
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ge
ni
ta
l C
M
V
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fe
ct
io
n,
 b
y 
H
IV
 st
at
us
N
o 
di
ffe
re
nc
es
 in
 c
on
ge
ni
ta
l 
CM
V
 in
fe
ct
io
n 
fre
qu
en
cy
,
 
by
 H
IV
 st
at
us
: 0
 o
f 4
 H
IV
-
in
fe
ct
ed
 in
fa
n
ts
 h
ad
 C
M
V
 
in
fe
ct
io
n 
as
 c
om
pa
re
d 
to
 1
0 
o
f 3
29
 H
IV
-
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po
se
d 
u
n
in
fe
ct
ed
 in
fa
n
ts
 (3
%;
 P 
=
 
1.
00
)
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rg
e 
sa
m
pl
e 
o
f H
IV
-
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po
se
d 
in
fa
n
ts
 
ev
al
ua
te
d
Sm
al
l s
am
pl
e 
of
 
H
IV
-
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iv
e 
in
fa
n
ts
 w
ith
 C
M
V
 
re
su
lts
 (n
 = 
4);
 no
 
po
stn
at
al
 C
M
V
 
te
st
in
g 
co
nd
uc
te
d
K
ha
m
du
an
g 
et
 a
l [
28
], 
20
11
Th
ai
la
nd
, 
19
97
– 
20
01
, 
re
tr
os
pe
ct
iv
e 
ca
se
-c
o
n
tr
ol
 
st
ud
y
29
3 
to
ta
l: 
H
IV
-
in
fe
ct
ed
 
in
fa
n
ts
 w
er
e 
m
at
ch
ed
 to
 
H
IV
-
ex
po
se
d 
u
n
in
fe
ct
ed
 
in
fa
n
ts
, b
y 
m
at
er
na
l 
H
IV
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N
A
 
le
v
el
; 2
31
 
ev
al
ua
te
d 
fo
r 
co
n
ge
ni
ta
l 
CM
V
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fe
ct
io
n,
 
an
d 
18
1 
ev
al
ua
te
d 
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r 
po
stn
at
al
 
CM
V
 
in
fe
ct
io
n
Pl
as
m
a 
or
 se
ru
m
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en
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t 
ag
e 
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 m
o 
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r C
M
V
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G
 
an
tib
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v
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B
M
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 C
M
V
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Ex
ac
t c
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l l
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ist
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n 
w
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d 
to
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m
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ro
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f 
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n
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 c
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n,
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H
IV
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us
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f 
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e 
w
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 c
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l 
CM
V
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ct
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y 
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al
l 
H
IV
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n 
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s; 
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d 
o
v
er
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l C
M
V
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fe
ct
io
n 
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qu
en
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 (i
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lud
ing
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n
ge
ni
ta
l),
 by
 ov
er
al
l H
IV
 
st
at
us
A
m
on
g 
in
fa
n
ts
 w
ith
 in
 u
te
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H
IV
 re
su
lts
, 7
 o
f 2
7 
H
IV
-
in
fe
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fa
n
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 (2
6%
) h
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n
ge
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l C
M
V
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fe
ct
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m
pa
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to
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 o
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H
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fe
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n
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; P
 
=
 .
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); 
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g a
ll 
in
fa
n
ts
 w
ith
 H
IV
 re
su
lts
, 1
0 
o
f 7
1 
H
IV
-
in
fe
ct
ed
 in
fa
n
ts
 
(14
%)
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d c
on
ge
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al 
CM
V 
in
fe
ct
io
n 
as
 c
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pa
re
d 
to
 5
 o
f 
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0 
H
IV
-
 
ex
po
se
d 
u
n
in
fe
ct
ed
 in
fa
n
ts
 (3
%;
 P 
=
 .
00
9);
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on
g a
ll i
nfa
n
ts
 w
ith
 
H
IV
 re
su
lts
, o
v
er
al
l C
M
V
 
in
fe
ct
io
n 
w
as
 m
o
re
 c
o
m
m
o
n
 
in
 H
IV
-
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fe
ct
ed
 in
fa
n
ts
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s 
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m
pa
re
d 
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 H
IV
-
ex
po
se
d 
u
n
in
fe
ct
ed
 in
fa
n
ts
 (8
4%
 vs
 
63
%
, r
es
pe
ct
iv
el
y;
 P
 
<
 .0
01
)
La
rg
e 
sa
m
pl
e 
o
f H
IV
-
in
fe
ct
ed
 
in
fa
n
ts
 w
ith
 
CM
V
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su
lts
; 
as
se
ss
ed
 
co
n
ge
ni
ta
l a
nd
 
po
stn
at
al
 C
M
V
 
in
fe
ct
io
n;
 
in
fa
n
t H
IV
 
in
fe
ct
io
n 
sta
tu
s 
de
te
rm
in
ed
 fo
r 
in
 u
te
ro
 a
nd
 
in
tra
pa
rtu
m
 
pe
rio
ds
; 
in
fe
re
nc
es
 c
an
 
be
 d
ra
w
n
 a
bo
ut
 
th
e 
te
m
po
ra
l 
re
la
tio
ns
hi
p 
be
tw
ee
n 
H
IV
 
an
d 
CM
V
 
tr
an
sm
iss
io
n
Ti
m
in
g 
of
 C
M
V
 
in
fe
ct
io
n 
w
as
 n
o
t 
de
te
rm
in
ed
 fo
r 
26
%
 o
f H
IV
-
 
in
fe
ct
ed
 in
fa
n
ts
 a
nd
 
18
%
 o
f H
IV
-
ex
po
se
d,
 
u
n
in
fe
ct
ed
 in
fa
n
ts
 
w
ith
 C
M
V
 
in
fe
ct
io
n
Fr
ed
er
ic
k 
et
 a
l [
12
], 
20
12
U
ni
te
d 
St
at
es
, 
19
88
–2
00
6,
 
pr
os
pe
ct
iv
e 
co
ho
rt 
stu
dy
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4 
to
ta
l: 
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8 
ev
al
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te
d 
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r 
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n
ge
ni
ta
l 
CM
V
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fe
ct
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d 
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3 
ev
al
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po
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at
al
 
CM
V
 
in
fe
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n
U
rin
e 
an
d 
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al
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 c
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re
Fi
sh
er
 ex
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t t
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w
as
 u
se
d 
to
 c
om
pa
re
 p
ro
po
rti
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s o
f 
in
fa
n
ts
 w
ith
 c
on
ge
ni
ta
l 
CM
V
 in
fe
ct
io
n,
 b
y 
H
IV
 
st
at
us
; a
nd
 th
os
e 
w
ith
 
pe
rin
at
al
/e
ar
ly
 p
os
tn
at
al
 
CM
V
 in
fe
ct
io
n,
 b
y 
H
IV
 
st
at
us
Co
ng
en
ita
l C
M
V
 re
su
lts
 d
id
 
n
o
t d
iff
er
 b
y 
in
fa
n
t H
IV
 
st
at
us
: 1
 o
f 2
1 
H
IV
-
in
fe
ct
ed
 
in
fa
n
ts
 (4
.8%
) h
ad
 C
M
V 
in
fe
ct
io
n 
as
 c
om
pa
re
d 
to
 8
 o
f 
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7 
H
IV
-
 
ex
po
se
d 
u
n
in
fe
ct
ed
 in
fa
n
ts
 (3
.5%
; P
 
=
 .
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); 
pe
rin
ata
l/e
arl
y 
po
stn
at
al
 C
M
V
 in
fe
ct
io
n 
w
as
 m
o
re
 p
re
v
al
en
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n 
H
IV
-
in
fe
ct
ed
 in
fa
n
ts
 (9
 of
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La
rg
e 
sa
m
pl
e 
o
f H
IV
-
ex
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se
d 
in
fa
n
ts
 
ev
al
ua
te
d;
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ed
 
co
n
ge
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po
stn
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 C
M
V
 
in
fe
ct
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n;
 
lo
ng
itu
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na
l 
st
ud
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de
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n 
Sm
al
l s
am
pl
e 
of
 
H
IV
-
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sit
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e 
in
fa
n
ts
 w
ith
 C
M
V
 
re
su
lts
 (n
 = 
21
 fo
r 
co
n
ge
ni
ta
l o
ut
co
m
e 
an
d 
n 
= 
32
 
pe
rin
at
al
/e
ar
ly
 
po
stn
at
al
 o
ut
co
m
e);
 
tim
in
g 
of
 H
IV
 
in
fe
ct
io
n 
w
as
 
u
n
kn
ow
n
, 
so
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 o
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 D
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R
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%
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d t
o 
H
IV
-
u
n
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 in
fa
n
ts
 (4
3 
o
f 3
61
 [1
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%
]; 
P 
<
 .0
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r p
os
tn
at
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re
su
lts
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V
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 b
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re
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os
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ev
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n
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CM
V
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 D
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m
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M
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 ex
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t w
as
 u
se
d 
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 c
om
pa
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ro
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s o
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in
fa
n
ts
 w
ith
 a
nd
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e 
w
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t c
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l C
M
V
 
in
fe
ct
io
n,
 b
y 
H
IV
 st
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Co
ng
en
ita
l C
M
V
 in
fe
ct
io
n 
w
as
 m
o
re
 c
o
m
m
o
n
 a
m
o
n
g 
H
IV
-
 
in
fe
ct
ed
 in
fa
n
ts
 (3
 of
 
30
 [1
0%
]) 
as 
co
mp
are
d t
o 
H
IV
-
ex
po
se
d 
un
in
fe
ct
ed
 
in
fa
n
ts
 (8
 of
 24
2 [
2.3
%]
; P
 
=
 .
04
9,
 af
te
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dju
stm
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r 
m
iss
in
g 
da
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)
La
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e 
sa
m
pl
e 
o
f H
IV
-
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se
d 
in
fa
n
ts
 
ev
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te
d
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l C
M
V
 
te
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w
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n
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ed
 b
u
t o
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y 
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o
n
g 
H
IV
-
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se
d 
un
in
fe
ct
ed
 
in
fa
n
ts
A
bb
re
v
ia
tio
ns
: I
gG
, i
m
m
un
og
lo
bu
lin
 G
; I
gM
, i
m
m
un
og
lo
bu
lin
 M
; P
BM
C,
 p
er
ip
he
ra
l b
lo
od
 m
on
on
uc
le
ar
 c
el
l; 
PC
R,
 p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n.
a C
al
cu
la
te
d 
by
 a
ut
ho
rs
 o
f t
hi
s s
ys
te
m
at
ic
 re
v
ie
w
,
 
u
sin
g 
da
ta
 a
bs
tra
ct
ed
 fr
om
 th
e 
ar
tic
le
.
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re
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os
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-
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n
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–3
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m
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 re
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rra
l
N
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ed
; F
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ex
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t t
es
ta
 
w
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to
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m
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s o
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in
fa
n
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ho
 d
ie
d,
 b
y 
CM
V
 st
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11
 H
IV
-
in
fe
ct
ed
 c
hi
ld
re
n 
(46
%)
 w
ere
 
co
in
fe
ct
ed
 w
ith
 C
M
V;
 7
 o
f 1
1 
CM
V-
co
in
fe
ct
ed
 c
hi
ld
re
n 
(64
%)
 di
ed
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 co
mp
are
d 
to
 3
 o
f 1
3 
CM
V-
n
eg
at
iv
e 
ch
ild
re
n 
(23
%)
; 
au
th
or
s r
ep
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te
d 
th
at
 th
e 
di
ffe
re
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e 
w
as
 
st
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al
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ifi
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 (P
 
<
 .0
5),
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t P
=
.0
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sh
er
 ex
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t t
es
t
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dy
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m
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H
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-
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 c
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n
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e 
of
 
H
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-
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e 
in
fa
n
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 re
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lts
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n
o
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w
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 b
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in
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 C
M
V
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op
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t a
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], 
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U
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, 
re
tr
os
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stu
dy
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ed
 in
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n
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an
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oo
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n 
in
 th
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fir
st 
w
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 c
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w
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 d
ie
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V
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) H
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-
in
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 c
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w
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 d
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V
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fe
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ed
 c
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 d
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n
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n
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 re
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lts
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fe
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n
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n
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f C
M
V-
 
co
in
fe
ct
ed
 
in
fa
n
ts
 (1
5) 
we
re 
CM
V
 p
os
iti
v
e 
w
ith
in
 fi
rs
t y
 o
f 
lif
e,
 b
u
t r
es
ul
ts 
w
er
e 
n
o
t 
st
ra
tif
ie
d 
by
 a
ge
 
at
 C
M
V
 
in
fe
ct
io
n
Ch
an
dw
an
i e
t a
l [
26
], 
19
96
U
ni
te
d 
St
at
es
, 1
98
9–
19
93
, 
pr
os
pe
ct
iv
e 
co
ho
rt 
stu
dy
37
 H
IV
-
in
fe
ct
ed
 in
fa
n
ts
 
te
st
ed
 fo
r C
M
V
 in
fe
ct
io
n 
by
 a
ge
 6
 m
o
A
na
ly
sis
 o
f c
ov
ar
ia
nc
e 
w
as
 u
se
d 
to
 ev
al
ua
te
 
ag
e-
 a
dju
ste
d 
di
ffe
re
nc
es
 in
 
qu
an
tit
at
iv
e 
v
ar
ia
bl
es
11
 H
IV
-
in
fe
ct
ed
 in
fa
n
ts
 (3
0%
) w
ere
 
co
in
fe
ct
ed
 w
ith
 C
M
V
 in
 th
e 
fir
st 
6 
m
o 
of
 
lif
e,
 o
f w
ho
m
 5
 (4
5%
) d
ev
el
op
ed
 
sy
m
pt
om
at
ic
 d
ise
as
e,
 w
ith
 4
 o
f t
he
se
 5
 
dy
in
g 
w
ith
in
 1
0 
m
o 
of
 d
ia
gn
os
is;
 m
ea
n 
p2
4 
an
tig
en
 c
on
ce
nt
ra
tio
ns
 w
er
e 
hi
gh
er
 in
 C
M
V-
co
in
fe
ct
ed
 in
fa
n
ts
 a
s 
co
m
pa
re
d 
to
 C
M
V
 
u
n
in
fe
ct
ed
 in
fa
n
ts
 (3
13
 pg
/m
L 
vs
 21
2 
pg
/m
L;
 P
 
=
 .
04
) a
t a
ge
 6 
mo
; m
ea
n C
D8
+
 
T-
ly
m
ph
oc
yt
e 
pr
op
or
tio
n 
w
as
 s
ig
ni
fic
an
tly
 
hi
gh
er
 a
m
on
g 
CM
V-
 
co
in
fe
ct
ed
 in
fa
n
ts
 a
s 
co
m
pa
re
d 
to
 C
M
V-
 
u
n
in
fe
ct
ed
 in
fa
n
ts
 (3
4%
 
v
s 
24
%
; P
 
=
 .
03
) a
t a
ge
 6 
mo
; m
ea
n C
D4
+
 
T-
ly
m
ph
oc
yt
e 
pr
op
or
tio
n 
w
as
 n
o
t d
iff
er
en
t 
by
 C
M
V
 st
at
us
 (3
0%
 vs
 31
%;
 P 
=
 .
85
) a
t 
ag
e 
6 
m
o
Lo
ng
itu
di
na
l s
tu
dy
Sm
al
l s
am
pl
e 
of
 
H
IV
-
po
sit
iv
e 
in
fa
n
ts
 w
ith
 
CM
V
 re
su
lts
 
w
ith
in
 fi
rs
t y
ea
r 
o
f l
ife
 (n
 = 
37
); 
su
rv
iv
al
 d
at
a 
w
er
e 
n
o
t 
pr
ov
id
ed
 fo
r 
CM
V-
n
eg
at
iv
e 
in
fa
n
ts
; i
nc
id
en
t 
CM
V
 c
ou
ld
 n
ot
 
be
 a
ss
es
se
d
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R
ef
er
en
ce
, 
Pu
bl
ic
at
io
n 
Ye
a
r
St
ud
y 
Si
te
, 
Pe
ri
od
, 
D
es
ig
n
N
o.
 o
f H
IV
-
In
fe
ct
ed
 
In
fa
nt
s F
o
llo
w
ed
St
at
ist
ic
al
 M
et
ho
d(
s)
D
ise
as
e 
Pr
o
gr
es
sio
n 
R
es
ul
t(s
)
St
re
n
gt
h(
s)
W
ea
kn
es
s(e
s)
D
oy
le
 e
t a
l [
21
], 
19
96
U
ni
te
d 
St
at
es
, 1
98
8–
19
95
, 
re
tr
os
pe
ct
iv
e 
co
ho
rt 
stu
dy
24
 H
IV
-
in
fe
ct
ed
 in
fa
n
ts
 
te
st
ed
 fo
r C
M
V
 d
ur
in
g 
ag
e 
≤2
 m
o
St
ud
en
t t
 
te
st
 w
as
 u
se
d 
to
 a
na
ly
ze
 q
ua
nt
ita
tiv
e 
v
ar
ia
bl
es
; K
ap
la
n–
M
ei
er
 
m
et
ho
d 
w
as
 u
se
d 
to
 
co
m
pa
re
 su
rv
iv
al
, b
y 
CM
V
 st
at
us
6 
H
IV
-
in
fe
ct
ed
 in
fa
n
ts
 (2
5%
) a
cq
uir
ed
 C
M
V 
in
fe
ct
io
n 
du
rin
g 
ag
e 
≤2
 m
o;
 m
ea
n 
ab
so
lu
te
 
CD
4+
 
T-
ly
m
ph
oc
yt
e 
co
un
t w
as
 s
ig
ni
fic
an
tly
 
lo
w
er
 fo
r C
M
V-
co
in
fe
ct
ed
 in
fa
n
ts
 a
s 
co
m
pa
re
d 
to
 C
M
V-
n
eg
at
iv
e 
in
fa
n
ts
 (6
43
 vs
 
15
90
 ce
lls
/m
3 ;
 P
 
=
 .
00
4) 
at 
ag
e 6
 m
o; 
me
an
 
CD
4+
 
T-
ly
m
ph
oc
yt
es
 p
ro
po
rti
on
 w
as
 
sig
ni
fic
an
tly
 lo
w
er
 fo
r C
M
V-
co
in
fe
ct
ed
 
in
fa
n
ts
 a
s 
co
m
pa
re
d 
to
 C
M
V-
n
eg
at
iv
e 
in
fa
n
ts
 (1
6 v
s 3
0%
; P
 
=
 .
04
) a
t a
ge
 6 
mo
; 
m
ea
n
 r
at
io
s o
f C
D
4+
 
to
 C
D
8+
 
T 
ly
m
ph
oc
yt
es
 w
er
e 
sig
ni
fic
an
tly
 lo
w
er
 fo
r 
CM
V-
co
in
fe
ct
ed
 in
fa
n
ts
 a
s 
co
m
pa
re
d 
to
 
CM
V-
n
eg
at
iv
e 
in
fa
n
ts
 (0
.48
 vs
 1.
26
; P
 
=
 .
04
) a
t a
ge
 6 
mo
; m
ea
n s
urv
iva
l t
im
e 
fo
r 
H
IV
-
po
sit
iv
e 
in
fa
n
ts
 c
oi
nf
ec
te
d 
w
ith
 C
M
V
 
w
as
 2
5 
m
o,
 w
hi
le
 m
ea
n 
su
rv
iv
al
 ti
m
e 
fo
r 
CM
V-
n
eg
at
iv
e 
w
as
 3
9 
m
o 
(P
 
=
 .
08
8)
Lo
ng
itu
di
na
l s
tu
dy
 
fo
cu
se
d 
on
 c
on
ge
ni
ta
l 
CM
V
 in
fe
ct
io
n
Sm
al
l s
am
pl
e 
of
 
H
IV
-
po
sit
iv
e 
in
fa
n
ts
 w
ith
 
CM
V
 re
su
lts
K
o
v
ac
s 
et
 a
l [
22
], 
19
99
U
ni
te
d 
St
at
es
, 
pr
os
pe
ct
iv
e 
co
ho
rt 
stu
dy
75
 H
IV
-
in
fe
ct
ed
 in
fa
n
ts
K
ap
la
n–
M
ei
er
 m
et
ho
d 
w
as
 u
se
d 
to
 c
om
pa
re
 
su
rv
iv
al
, b
y 
CM
V
 
st
at
us
; a
 g
en
er
al
iz
ed
 
W
ilc
ox
on
 te
st 
w
as
 u
se
d 
to
 c
om
pa
re
 o
v
er
al
l 
in
ci
de
nc
e
40
 o
f 7
5 
H
IV
-
in
fe
ct
ed
 in
fa
n
ts
 (5
3%
) w
ere
 
co
in
fe
ct
ed
 w
ith
 C
M
V
 b
y 
ag
e 
18
 m
o;
 b
y 
ag
e 
18
 m
o,
 c
oi
nf
ec
te
d 
in
fa
n
ts
 h
ad
 h
ig
he
r r
at
es
 o
f 
H
IV
 d
ise
as
e 
pr
og
re
ss
io
nb
 
(70
% 
vs
 30
%;
 P 
=
 .
00
1);
 co
inf
ec
ted
 in
fan
ts
 h
ad
 h
ig
he
r r
at
es
 
o
f C
D
C 
cl
as
s C
 sy
m
pt
om
s o
r d
ea
th
 (5
3%
 vs
 
22
%
; P
 
=
 .
00
8);
 cu
mu
lat
ive
 1
8-
m
on
th
 d
ea
th
 
ra
te
 w
as
 5
.0
%
 fo
r c
oi
nf
ec
te
d 
in
fa
n
ts
 a
s 
co
m
pa
re
d 
to
 0
%
 fo
r i
nf
an
ts
 w
ith
ou
t C
M
V-
in
fe
ct
io
n,
 th
is 
di
ffe
re
nc
e 
in
cr
ea
se
d 
w
ith
 a
ge
 
(27
.5%
 vs
 0%
 at
 3 
y a
nd
 30
% 
vs
 9%
 at
 4 
y; 
P 
=
 .
06
)
Lo
ng
itu
di
na
l s
tu
dy
 d
es
ig
n 
fo
r p
os
tn
at
al
 re
su
lts
; 
as
se
ss
ed
 c
on
ge
ni
ta
l a
nd
 
po
stn
at
al
 C
M
V
 in
fe
ct
io
n
R
es
ul
ts 
no
t 
pr
ov
id
ed
 fo
r 
CM
V
 st
at
us
 b
y 
ag
e 
12
 m
o
G
ab
rie
l e
t a
l [
32
], 
20
07
Sp
ai
n,
 1
98
7–
20
02
, 
pr
os
pe
ct
iv
e 
co
ho
rt 
stu
dy
81
 in
fa
n
ts
 in
fe
ct
ed
 w
ith
 
H
IV
 d
ur
in
g 
ag
e 
≤1
2 
m
o
A
n 
ac
tu
ar
ia
l m
et
ho
d 
an
d 
lo
g-
 ra
nk
 te
st 
w
er
e 
us
ed
 
to
 c
om
pa
re
 su
rv
iv
al
 
cu
rv
es
, 
by
 C
M
V
 st
at
us
; 
St
ud
en
t t
 
te
st
 w
as
 u
se
d 
to
 c
om
pa
re
 q
ua
nt
ita
tiv
e 
v
ar
ia
bl
es
16
 H
IV
-
in
fe
ct
ed
 in
fa
n
ts
 (2
0%
) w
ere
 
co
in
fe
ct
ed
 w
ith
 C
M
V;
 th
er
e 
w
as
 n
o
 
di
ffe
re
nc
e 
in
 d
ea
th
, b
y 
CM
V
 st
at
us
, a
t a
ge
 2
 
y 
(20
% 
of 
co
inf
ec
ted
 in
fan
ts
 a
s 
co
m
pa
re
d 
to
 
24
%
 o
f C
M
V-
n
eg
at
iv
e 
in
fa
n
ts
); 
me
an
 
ab
so
lu
te
 C
D
4+
 
T-
 
ly
m
ph
oc
yt
e 
co
un
ts 
w
er
e 
th
e 
sa
m
e 
in
 C
M
V-
co
in
fe
ct
ed
 in
fa
n
ts
 a
nd
 
CM
V-
 
u
n
in
fe
ct
ed
 in
fa
n
ts
 (1
46
4 v
s 1
77
0 
ce
lls
/m
3 ;
 P
 
=
 .
46
) a
t a
ge
 1 
y; 
me
an
 C
D4
+
 
T-
 
ly
m
ph
oc
yt
e 
pe
rc
en
ta
ge
 w
as
 th
e 
sa
m
e 
in
 
CM
V-
co
in
fe
ct
ed
 in
fa
n
ts
 a
nd
 C
M
V-
 
u
n
in
fe
ct
ed
 in
fa
n
ts
 (2
8.7
 vs
 29
.6%
; P
 
=
 .
85
) 
at
 a
ge
 1
 y
; m
ea
n 
ra
tio
s o
f C
D
4+
 
to
 C
D
8+
 
T 
ly
m
ph
oc
yt
es
 w
er
e 
th
e 
sa
m
e 
fo
r C
M
V-
co
in
fe
ct
ed
 in
fa
n
ts
 a
nd
 C
M
V-
 
n
eg
at
iv
e 
in
fa
n
ts
 (1
.07
 vs
 1.
4; 
P 
=
 .
32
) a
t a
ge
 1 
y; 
m
ea
n
 H
IV
 lo
ad
 w
as
 h
ig
he
r i
n 
CM
V-
n
eg
at
iv
e,
 H
IV
-
in
fe
ct
ed
 in
fa
n
ts
 a
s 
co
m
pa
re
d 
to
 c
oi
nf
ec
te
d 
in
fa
n
ts
 (5
49
 34
3 v
s 6
52
3; 
P 
=
 .
02
)
Lo
ng
itu
di
na
l s
tu
dy
 a
m
on
g 
H
IV
-
in
fe
ct
ed
 c
hi
ld
re
n
Co
un
ts 
fo
r 
de
at
hs
 n
ot
 
pr
ov
id
ed
; 
st
at
ist
ic
al
 
co
m
pa
ris
on
s i
n 
su
rv
iv
al
 a
na
ly
se
s 
w
er
e 
n
o
t c
le
ar
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A
bb
re
v
ia
tio
n:
 C
D
C,
 C
en
te
rs
 fo
r D
ise
as
e 
Co
nt
ro
l a
nd
 P
re
v
en
tio
n.
a C
al
cu
la
te
d 
by
 a
ut
ho
rs
 o
f t
hi
s s
ys
te
m
at
ic
 re
v
ie
w
,
 
u
sin
g 
da
ta
 a
bs
tra
ct
ed
 fr
om
 th
e 
ar
tic
le
.
b D
ef
in
ed
 a
s t
he
 p
re
se
nc
e 
of
 C
D
C-
de
fin
ed
 c
la
ss
 C
 sy
m
pt
om
s, 
CD
4 
<7
50
 ce
lls
/μ
L 
at
 1
 y
ea
r o
f a
ge
, o
r C
D
4 
< 
50
0 
ce
lls
/μ
L 
at
 1
8 
m
on
th
s o
f a
ge
.
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